Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, single-dose, pharmacokinetic study in 9 obese and 9 age-, sex-, ideal
body weight- matched non-obese subjects. Qualifying subjects who have completed an informed
consent will receive a single intravenous dose of tedizolid with the collection of 11 blood
samples over 72 hours post dose.
Phase:
Phase 4
Details
Lead Sponsor:
Albany College of Pharmacy and Health Sciences Amit.Pai